Production (Stage)
Gain Therapeutics, Inc.
GANX
$1.80
$0.010.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.22M | 9.91M | 275.40K | 287.30K | 2.47M |
| Gross Profit | -2.22M | -9.91M | -275.40K | -287.30K | -2.47M |
| SG&A Expenses | 2.15M | 2.14M | 1.84M | 3.75M | 1.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.37M | 3.33M | 4.46M | 8.18M | 4.38M |
| Operating Income | -4.37M | -3.33M | -4.46M | -8.18M | -4.38M |
| Income Before Tax | -4.43M | -3.26M | -4.47M | -8.14M | -3.99M |
| Income Tax Expenses | 100.50K | 504.70K | 11.00K | 1.20K | 19.90K |
| Earnings from Continuing Operations | -4.53M | -3.77M | -4.49M | -8.14M | -4.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.53M | -3.77M | -4.49M | -8.14M | -4.01M |
| EBIT | -4.37M | -3.33M | -4.46M | -8.18M | -4.38M |
| EBITDA | -4.36M | -3.32M | -4.45M | -8.17M | -4.37M |
| EPS Basic | -0.16 | -0.14 | -0.17 | -0.42 | -0.22 |
| Normalized Basic EPS | -0.10 | -0.07 | -0.11 | -0.26 | -0.14 |
| EPS Diluted | -0.16 | -0.14 | -0.17 | -0.42 | -0.22 |
| Normalized Diluted EPS | -0.10 | -0.07 | -0.11 | -0.26 | -0.14 |
| Average Basic Shares Outstanding | 28.69M | 27.71M | 26.53M | 19.22M | 17.98M |
| Average Diluted Shares Outstanding | 28.69M | 27.71M | 26.53M | 19.22M | 17.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |